NextPlat (NXPL) Liabilities from Discontinued Operations (2010 - 2023)
NextPlat's (NXPL) quarterly Liabilities from Discontinued Operations came in at $112397.0 in Q1 2023, little changed year-over-year from $112397.0 in Q1 2022, and little changed quarter-over-quarter from $112000.0 in Q4 2022.
Analysis
NextPlat (NXPL) Liabilities from Discontinued Operations (2010 - 2023) Analysis & Trends
NextPlat (NXPL) has reported Liabilities from Discontinued Operations for 14 consecutive years, with $112397.0 the latest figure, recorded in Q1 2023.
- On a quarterly basis, Liabilities from Discontinued Operations changed 0.0% year-over-year to $112397.0 in Q1 2023; TTM through Mar 2023 was $112397.0, a 0.0% change from a year earlier, with the FY2022 full-year figure at $112000.0, changed 0.35% from the prior year.
- Liabilities from Discontinued Operations was $112397.0 for Q1 2023 at NextPlat, roughly flat from $112000.0 in the prior quarter.
- Over five years, Liabilities from Discontinued Operations peaked at $112397.0 in Q1 2019 and troughed at $112000.0 in Q4 2022.
- A 5-year average of $112373.6 and a median of $112397.0 in 2019 frame the typical range for Liabilities from Discontinued Operations.
- Across the five-year window, Liabilities from Discontinued Operations changed 0.0% in 2019 and decreased 0.35% in 2022, its largest moves.
- Over 5 years, Liabilities from Discontinued Operations stood at $112397.0 in 2019, then changed by 0.0% to $112397.0 in 2020, then changed by 0.0% to $112397.0 in 2021, then dropped by 0.35% to $112000.0 in 2022, then rose by 0.35% to $112397.0 in 2023.
- The last three Liabilities from Discontinued Operations figures came in at $112397.0 (Q1 2023), $112000.0 (Q4 2022), and $112397.0 (Q3 2022), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | 112,397.00 |
| Dec 31, 2022 | 112,000.00 |
| Sep 30, 2022 | 112,397.00 |
| Jun 30, 2022 | 112,397.00 |
| Mar 31, 2022 | 112,397.00 |
| Dec 31, 2021 | 112,397.00 |
| Sep 30, 2021 | 112,397.00 |
| Jun 30, 2021 | 112,397.00 |
| Mar 31, 2021 | 112,397.00 |
| Dec 31, 2020 | 112,397.00 |
| Sep 30, 2020 | 112,397.00 |
| Jun 30, 2020 | 112,397.00 |
| Mar 31, 2020 | 112,397.00 |
| Dec 31, 2019 | 112,397.00 |
| Sep 30, 2019 | 112,397.00 |
| Jun 30, 2019 | 112,397.00 |
| Mar 31, 2019 | 112,397.00 |
| Dec 31, 2018 | 112,397.00 |
| Sep 30, 2018 | 112,397.00 |
| Jun 30, 2018 | 112,397.00 |